Suppr超能文献

副干酪乳杆菌Shirota在生物乳化剂、细菌素和脂肪酶生产方面的生物技术潜力。

Biotechnological potential of Lacticaseibacillus paracasei Shirota for bioemulsifier, bacteriocin and lipase production.

作者信息

de Medeiros Naiany Silva, da Nóbrega Felipe Ferreira, Lopes Patricia Santos, de Assis Cristiane Fernandes, Sousa Júnior Francisco Canindé de

机构信息

Departamento de Farmácia, Universidade Federal do Rio Grande do Norte - UFRN, Natal, RN, 59012-570, Brazil.

Departamento de Ciências Farmacêuticas, Universidade Federal de São Paulo - UNIFESP, Diadema, SP, 09972-270, Brazil.

出版信息

Braz J Microbiol. 2024 Dec;55(4):3229-3238. doi: 10.1007/s42770-024-01534-4. Epub 2024 Oct 10.

Abstract

This study aimed to evaluate the biotechnological potential of Lacticaseibacillus paracasei Shirota to produce biosurfactants/bioemulsifiers, lipase, and bacteriocins. The production of biosurfactants/bioemulsifiers was evaluated through a central composite rotational design (CCRD) 2. L. paracasei produced bioemulsifiers using MRS supplemented with 4.8% glycerol and pH 6 or 7. In addition, the culture supernatants of L. paracasei were tested for antioxidant, antidiabetic, and lipolytic activities. The tested supernatants did not exhibit antioxidant activity. On the other hand, they showed inhibitory activity for amyloglucosidase (20.7% and 23.9%) and lipolytic activity (16.12 and 19.00 U/mL). In addition, a CCRD 2 was performed to evaluate the production of bacteriocins. The peptone and lactose concentration variables, as well as pH positively influenced the production of bacteriocins by L. paracasei. In conclusion, L. paracasei is a viable source of antidiabetic metabolites, bacteriocins, bioemulsifiers, and lipase, suggesting that they are promising to be applied in the pharmaceutical, cosmetic, environmental, food, and biomedical industries.

摘要

本研究旨在评估副干酪乳杆菌代田株产生生物表面活性剂/生物乳化剂、脂肪酶和细菌素的生物技术潜力。通过中心复合旋转设计(CCRD)2评估生物表面活性剂/生物乳化剂的产生。副干酪乳杆菌使用添加4.8%甘油且pH值为6或7的MRS培养基产生生物乳化剂。此外,还测试了副干酪乳杆菌的培养上清液的抗氧化、抗糖尿病和脂肪分解活性。测试的上清液未表现出抗氧化活性。另一方面,它们对淀粉葡萄糖苷酶表现出抑制活性(20.7%和23.9%)以及脂肪分解活性(16.12和19.00 U/mL)。此外,进行了CCRD 2以评估细菌素的产生。蛋白胨和乳糖浓度变量以及pH值对副干酪乳杆菌产生细菌素具有积极影响。总之,副干酪乳杆菌是抗糖尿病代谢物、细菌素、生物乳化剂和脂肪酶的可行来源,表明它们有望应用于制药、化妆品、环境、食品和生物医学行业。

相似文献

8
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验